血清CA153 hMAM CXCL8联合诊断乳腺癌的应用价值

doi:10.3969/j.issn.1006-6233.2025.03.014

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1332 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To study the clinical value of serum carbohydrate antigen 153 (CA153), human mammaglobin (hMAM) and C-X-C motif ligand 8 (CXCL8) in the diagnosis of breast cancer (BC). Methods: Eighty patients with BC (BC group), 80 patients with benign breast tumor (BBT group), and 80 patients with healthy physical examination (control group) who visited our hospital from January 2022 to December 2023 were enrolled in the study. Fasting venous blood was collected from the patients of BC group and BBT group on the next day of admission, and the patients of the control group on the morning of physical examination. Serum was extracted, CA153, and hMAM and CXCL8 were respectively detected by electrochemiluminescence and enzyme-linked immunosorbent assay (ELISA). The serum levels of CA153, hMAM and CXCL8 of the patients in the three groups were counted. Pearson correlation was used to analyze the correlation between serum CA153, hMAM, CXCL8 levels and tumor-node-metastasis (TNM) stage in BC group. The efficacy of CA153, hMAM and CXCL8 in the diagnosis of BC was evaluated by receiver operating characteristic (ROC) curve. Results: The serum CA153, hMAM and CXCL8 in BC group were significantly higher than those in BBT group and control group (P<0.05), and which in BBT group were significantly higher than those of the control group (P<0.05). The serum CA153, hMAM and CXCL8 in patients with stage I were significantly lower than those in patients with stages II, III, and which in patients with stage II were significantly lower than those of patients with stage III (P<0.05). The serum levels of CA153, hMAM and CXCL8 were positively correlated with TNM stage by Pearson correlation analysis (r=0.857, 1.137, 1.968, P<0.05). According to ROC curve analysis, the combined efficacy of serum CA153, hMAM and CXCL8 in the diagnosis of BC was significantly higher than that of the three alone. Conclusion: The levels of serum CA153, hMAM and CXCL8 in patients with BC are positively correlated with TNM stage, and the combination of serum CA153, hMAM and CXCL8 has high diagnostic value for BC.

Key words： Breast cancer CA153 hMAM CXCL8 Diagnostic value

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2025.03.014 OR http://www.hbyxzzs.cn/EN/Y2025/V31/I3/431

[1] Tarighati E,Keivan H,Mahani H.A review of prognostic and predictive biomarkers in breast cancer[J].Clin Exp Med,2023,23(1):1-16.
[2] Mishra A,Suman KH,Nair N,et al.An updated review on the role of the CXCL8-CXCR1/2 axis in the progression and metastasis of breast cancer[J].Mol Biol Rep,2021,48(9):6551-6561.
[3] 中国抗癌协会乳腺癌专业委员会.中国晚期乳腺癌临床诊疗专家共识( 2018版)[J].中华肿瘤杂志,2018,40(9):703-713.
[4] 中华预防医学会妇女保健分会乳腺保健与乳腺疾病防治学.乳腺纤维腺瘤诊治专家共识[J].中国实用外科杂志,2016,36(7):752-754.
[5] Fan Y,Chen X,Li H.Clinical value of serum biomarkers CA153,CEA,and white blood cells in predicting sentinel lymph node metastasis of breast cancer[J].Int Clin Exp Pathol,2020,13(11):2889-2894.
[6] Li J,Liu L,Feng Z,et al.Tumor markers CA15-3,CA125,CEA and breast cancer survival by molecular subtype:a cohort study[J].Breast Cancer,2020,27(4):621-630.
[7] Bel'skaya LV,Sarf EA,Loginova AI,et al.Potential diagnostic value of salivary tumor markers in breast,lung and ovarian cancer:a preliminary study[J].Curr Issues Mol Biol,2023,45(6):5084-5098.
[8] Mi J,Zhang H,Cao W,et al.FTO,PIK3CB serve as potential markers to complement CEA and CA15-3 for the diagnosis of breast cancer[J].Medicine (Baltimore),2023,102(42):35361.
[9] Ghasemi-Dehkordi P,Doosti A,Jami MS.The functions of azurin of Pseudomonas aeruginosa and human mammaglobin-A on proapoptotic and cell cycle regulatory genes expression in the MCF-7 breast cancer cell line[J].Saudi Biol Sci,2020,27(9):2308-2317.
[10] Milosevic B,Stojanovic B,Cvetkovic A,et al.The enigma of mammaglobin:redefining the biomarker paradigm in breast carcinoma[J].Int Mol Sci,2023,24(17):13407.
[11] Zhang Z,Wang H,Jin Y,et al.Potential of blood exosomal ENAH,SEPT9,EGF,MMP-9 and CXCL8 for the early screening of breast cancer[J].Oncol Lett,2022,24(6):460.
[12] Seale KN,Tkaczuk KHR.Circulating biomarkers in breast cancer[J].Clin Breast Cancer,2022,22(3):319-331.
[13] Bonacho T,Rodrigues F,Liberal J.Immunohistochemistry for diagnosis and prognosis of breast cancer:a review[J].Biotech Histochem,2020,95(2):71-91.
[14] Stepien S,Smycz-Kubanska M,Kruszniewska-Rajs C,et al.Clinical significance of the CXCL8/CXCR1/R2 signalling axis in patients with invasive breast cancer[J].Oncol Lett,2024,27(6):260.